Seres Therapeutics

Seres Therapeutics Employees

7 people indexed:

David Ege

EVP, Chief Technology Officer

9fk2@z9fw4k78x9bw4693f.vvz Sign up to see email

6y9b@65924ly8nf68n7892.fkf Sign up to see email
Eric Shaff

President, Chief Executive Officer

k8xgk6@k64znl02w7q401znq.563 Sign up to see email

234vq7@zb79490kw15q9dnwx.113 Sign up to see email
Lisa Von Moltke

EVP, Chief Medical Officer

19dq.5y125d@3wzd5fqwqy61dww6f.0q4 Sign up to see email

9xwf.y5g9b4@7904d9y6z81xxy224.gyq Sign up to see email
Marella Thorell

EVP, Chief Financial Officer

8jdv6xjd@gj29gyzq02ffwj1zq.5gq Sign up to see email

kvvfgdjz@g15f64f0b7xk0g5jz.djk Sign up to see email
Matthew Henn

EVP, Chief Scientific Officer

1lwk3@kjgf4b053x2l0qb3w.j56 Sign up to see email

l2dyx@89gv44q4gz64l5fw4.f3z Sign up to see email
Terri Young

EVP, Chief Commercial and Strategy Officer

732qk7@dl5l1df9zq0k14d2q.fkk Sign up to see email

69bjx5@qbq5zfl2k075xw8b5.308 Sign up to see email
Thomas J. DesRosier

EVP, Chief Legal Officer and Secretary

w1.6x858vbzl@fgbb5l2wv1x754qb5.z20 Sign up to see email

y9.75gn4bf0k@nywbb85g481x3v0nk.8y0 Sign up to see email

Seres Therapeutics Company Information

Seres Therapeutics is a biotechnology firm focused on the development of microbiome therapeutics. The company’s flagship product, VOWST, is an FDA-approved microbiota-based therapeutic designed to prevent recurrent Clostridioides difficile infection in adults. Seres Therapeutics is actively involved in clinical trials for a range of conditions including C. difficile infection, ulcerative colitis, and graft-versus-host disease. In addition to its internal efforts, the company has established a collaboration with Nestlé Health Science to advance its C. difficile and inflammatory bowel disease (IBD) programs outside North America. Seres operates research and manufacturing facilities in Cambridge, Massachusetts, with additional facilities in Irvine, California, and Tempe, Arizona. The company also runs a stool donation program, GoodNature, which supports the development of its microbiome therapeutics.

Report inaccurate information